MAPT and tauopathy: GSK3β activation has induced tauopathy-related phenotypes in mouse models (Terwel et al., 2008; Crespo-Biel et al., 2014), and GSK3β inhibitors have exhibited beneficial effects against tauopathy and neurodegeneration in tau transgenic mice (Uno et al., 2009; Martinez et al., 2011).